Pharmaceutical Sector

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said

Aurobindo Pharma now weighs mega IPO of Eugia Pharma Specialities to raise around Rs 4,500 crore

In May 2021, in a move to improve operational efficiency, Aurobindo Pharma had approved the transfer of its injectable assets into a subsidiary called Eugia Pharma Specialities Limited for “greater focus, attention and specialization” and also to “augment fund-raise and strategic tie-ups in future through joint ventures etc"

IndiaRF to acquire API, CRAMS business of Ind-Swift Laboratories for Rs 1,650 crore

Equity value of the transaction is worth Rs 850 crore, considering an approximate debt of Rs 800 crore

Lupin gets USFDA nod for birth-control pill

While Lupin is yet to declare the June quarter numbers, it reported a 14 percent on-year jump in net profit at Rs 236 crore in the March quarter

Is the pharma sector on the road to regaining its mojo?

Analysts believe fresh investments in R&D, the widespread China+1 sentiment, and the government's push for the sector through the PLI scheme and tighter regulations could work in favour of the domestic pharma sector.

Pharma Q4 preview: US launches, steady domestic growth to drive recovery

Expected revenue, operating profit margin growth to bolster the health of industry players

Are pharma cos poised for a bull ride? Here's what analysts believe

Alok Dalal of Jefferies believes the $27 billion domestic pharma industry is well-placed to achieve low double-digit growth in the coming years on increased spending on medicines as the population starts to age.

Natco Pharma proposes to buy back 1.64% stake for Rs 210 crore

The company said it will buyback fully paid-up equity shares at a price not exceeding Rs 700 a share, a maximum buyback price, against the current market price of Rs 568.

Wockhardt shuts manufacturing unit in US to cut down on costs

The closure of the Illinois-based manufacturing facility will not affect the availability of products in the US market, Wokhardt clarified.

PharmEasy to acquire 66.1% stake in Thyrocare for Rs 4,546 crore

Docon Technologies Pvt Ltd, a 100 percent subsidiary of PharmEasy's parent firm API, will be the acquirer and shall make an open offer for an additional 26 percent stake.

5 reasons why pharma stocks could still come under pressure

The recent set of results highlights the ills of the sector. Pharmaceutical companies are having a tough time with the US authorities pulling them up regularly for irregularities at one end, while on the other hand the companies are taking a hit on the revenue front at the international and domestic front.

Here is a wrap on US-FDA woes for Indian pharmaceutical sector

There is a lot of newsflow in pharmaceutical sector with regards to US-FDA. Watch accompanying video of CNBC-TV18's Ekta Batra for more details.

Budget 2017: Govt to frame new rules on medical devices to draw investments

These rules will be internationally harmonised and attract investments into this sector. This will reduce the cost of such devices," Finance Minister Arun Jaitley said.

India rejects 955 pharma patent applications in last 3 years

India has rejected as many as 955 patent applications in the pharmaceutical sector in the last three years.

India needs to incorporate changes in pharma sector: WHO RD

"There is no one model that suits all. We have health services which are solely by the government, by the private sector and those which are a mix of the public and the private sector.

Pharma exports growth heading for a sharp decline: Crisil

The pharmaceutical sector is heading for a tough time as exports growth in formulations (in US dollar terms) is expected to almost halve to 10-12 percent annually over the next five years, a report said.

US and EU regulators urge Indian drug cos to step up standards

India's USD 15 billion pharmaceutical industry, an increasingly important global supplier of cheaper generic medicines, has been dogged by concerns over quality issues after the US Food and Drug Administration banned a series of factories from producing medicines for the United States due to inadequate standards.

CCI extends deadline for bids to conduct pharma study

The anti-trust regulator is planning the study to understand whether there are unfair practices in this sector as part of larger efforts to clamp down on anti-competitive business practices and has also passed many orders in this regard.

India interested in reviving FTA talks with EU: Sitharam

Sitharaman said India believes that there should be free trade "but is it just India which is questioned on free trade. I would like to know how many countries actually completely follow the principles of free trade".

Comm Min may set up think-tank for pharmaceutical sector

The exports situation and other issues in pharmaceutical sector were discussed during a meeting convened by Commerce and Industry Minister Nirmala Sitharaman.

Pharma, food biz to benefit company by year end: Snowman

Ravi Kannan, CEO of Snowman Logistics says the company has added more than 150 refrigeration trucks and will require two quarters to get the optimum utilisation of over 95 percent.

Interact with CNBC-TV18: Pharma sector doing well, will continue to do so: Hiren Ved

Hiren Ved, Director & CIO, Alchemy Capital Management says he doesn‘t look at pharmaceutical as defensive or non defensive. He says the sector is doing extremely well and growth will continue irrespective. It is not as if the new government comes and the pharma sector will have no scope for growth and appreciation

Eyeing overseas listing; moved biz to S'pore arm: Jubilant

Jubilant Life Sciences says that the 30 percent transfer of its pharma business to the Singapore subsidiary was done as a part of its process to list internationally.

FIPB may defer FDI in pharma sector

The finance ministry may defer 10 proposals for FDI in pharmaceutical sector that are listed to be taken up at the FIPB (Foreign Investment Promotion Board) meeting on Friday, as the government is yet to review foreign investment policy in existing Indian drug companies.

EU fines Ranbaxy, others for blocking cheaper drugs

EU antitrust regulators fined nine drugmakers a total of 146 million euros on Wednesday for blocking the supply of cheaper medicines on the market, with a penalty of 94 million euros imposed on Denmark's Lundbeck .